Anticancer drug development guide :
Anticancer drug development guide : preclinical screening, clinical trials, and approval /
edited by Beverly A. Teicher, Paul A. Andrews.
- 2nd ed.
- Totowa, N.J. : Humana Press, c2004.
- xiv, 450 p. : ill. ; 26 cm. + 1 CD-ROM (4 3/4 in.)
- Cancer drug discovery and development .
Includes bibliographical references and index.
High-volume screening / Michel Pagä -- High-throughput screening in industry / Michael D. Boisclair ... [et al.] -- The NCI human tumor cell line (60-cell) screen: concept, implementation, and applications / Michael R. Boyd -- Human tumor screening / Axel-R. Hanauske, Susan G. Hilsenbeck, and Daniel D. Von Hoff -- Murine L1210 and P388 leukemias / William R. Waud -- In vivo methods for screening and preclinical testing: use of rodent solid tumors for drug discovery / Thomas Corbett ... [et al.] -- Human tumor xenograft models in NCI drug development / Michael C. Alley ... [et al.] -- Specialized in vitro/in vivo procedures employed by the NCI in preclinical drug evaluations / Melinda G. Hollingshead ... [et al.] -- Patient-like orthotopic metastatic models of human cancer / Robert M. Hoffman -- Preclinical models for combination therapy / Beverly A. Teicher -- Models for biomarkers and minimal residual tumor / Beverly A. Teicher -- Spontaneously occurring tumors in companion animals as models for drug development / David M. Vail and Douglas H. Thamm -- Nonclinical testing: from theory to practice / Denis Roy and Paul A. Andrews -- Nonclinical testing for oncology drug products / Paul A. Andrews and Denis Roy -- Nonclinical testing for oncology biologic products / Carolyn M. Laurenìot, Denis Roy, and Paul A. Andrews -- Working with the national cancer institute / Paul Thambi and Edward A. Sausville -- Phase I trial design and methodology for anticancer drugs / Patrick V. Acevedo, Deborah L. Toppmeyer, and Eric H. Rubin -- Phase II trials: conventional design and novel strategies in the era of targeted therapies / Keith T. Flaherty and Peter J. O'Dwyer -- Drug development in Europe: the academic perspective / Chris Twelves ... [et al.] -- The phase III clinical cancer trial / Ramzi N. Dagher and Richard Pazdur -- Assessing tumor-related symptoms and health-related quality of life in cancer clinical trials: a regulatory perspective / Judy H. Chiao, Grant Williams, and Donna Griebel -- The role of the oncology drug advisory committee in the FDA review process for oncologic products / Leslie A. Vaccari -- FDA role in cancer drug development and requirements for approval / Susan Flamm Honig.
Minimum system requirements: Adobe reader 6.0 or later.
1588292282 (alk. paper) 1592597394 (e-book)
2003024925
Antineoplastic agents--Development.
Antineoplastic Agents--standards.
Clinical Trials.
Drug Approval.
Drug Design.
Drug Evaluation, Preclinical.
RC271.C5 / A6722 2004
616.99/4061
QV 269 / A62953 2004
Includes bibliographical references and index.
High-volume screening / Michel Pagä -- High-throughput screening in industry / Michael D. Boisclair ... [et al.] -- The NCI human tumor cell line (60-cell) screen: concept, implementation, and applications / Michael R. Boyd -- Human tumor screening / Axel-R. Hanauske, Susan G. Hilsenbeck, and Daniel D. Von Hoff -- Murine L1210 and P388 leukemias / William R. Waud -- In vivo methods for screening and preclinical testing: use of rodent solid tumors for drug discovery / Thomas Corbett ... [et al.] -- Human tumor xenograft models in NCI drug development / Michael C. Alley ... [et al.] -- Specialized in vitro/in vivo procedures employed by the NCI in preclinical drug evaluations / Melinda G. Hollingshead ... [et al.] -- Patient-like orthotopic metastatic models of human cancer / Robert M. Hoffman -- Preclinical models for combination therapy / Beverly A. Teicher -- Models for biomarkers and minimal residual tumor / Beverly A. Teicher -- Spontaneously occurring tumors in companion animals as models for drug development / David M. Vail and Douglas H. Thamm -- Nonclinical testing: from theory to practice / Denis Roy and Paul A. Andrews -- Nonclinical testing for oncology drug products / Paul A. Andrews and Denis Roy -- Nonclinical testing for oncology biologic products / Carolyn M. Laurenìot, Denis Roy, and Paul A. Andrews -- Working with the national cancer institute / Paul Thambi and Edward A. Sausville -- Phase I trial design and methodology for anticancer drugs / Patrick V. Acevedo, Deborah L. Toppmeyer, and Eric H. Rubin -- Phase II trials: conventional design and novel strategies in the era of targeted therapies / Keith T. Flaherty and Peter J. O'Dwyer -- Drug development in Europe: the academic perspective / Chris Twelves ... [et al.] -- The phase III clinical cancer trial / Ramzi N. Dagher and Richard Pazdur -- Assessing tumor-related symptoms and health-related quality of life in cancer clinical trials: a regulatory perspective / Judy H. Chiao, Grant Williams, and Donna Griebel -- The role of the oncology drug advisory committee in the FDA review process for oncologic products / Leslie A. Vaccari -- FDA role in cancer drug development and requirements for approval / Susan Flamm Honig.
Minimum system requirements: Adobe reader 6.0 or later.
1588292282 (alk. paper) 1592597394 (e-book)
2003024925
Antineoplastic agents--Development.
Antineoplastic Agents--standards.
Clinical Trials.
Drug Approval.
Drug Design.
Drug Evaluation, Preclinical.
RC271.C5 / A6722 2004
616.99/4061
QV 269 / A62953 2004